20mins delayed


1 Year Return

Nyrada Inc Chart

Share price
Market Cap $19.09 million
Today's Movement
Prev. Close
Day Range -
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover

NYR Statistics

04 December

1,712 / 2,258

ASX Size Rank

1yr Return

vs Sector (1yr)


vs ASX 200 (1yr)


$19.09 million

Market Cap

Share Issue

76.36 million

All Ords (%)


Short Sold


Current Fundamentals

04 December


PE Ratio

EPS ($)


Earnings Yield


NTA ($)



Dividend Yield

DPS ($)


Gross Div. Yield


Gross DPS ($)


Company Overview

Nyrada Inc (NYR) is a preclinical stage, drug development company. The Company specialises in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. It focuses on areas of substantial unmet clinical need and has identified drug candidates with therapeutic and commercial potential, where few if any, effective or well-tolerated therapies exist. It currently has three wholly-owned drug programs:

Nyrada Inc Logo

Corporate Details

Head Office: Wilmington Delaware
Managing Director: James Bonnar
GICS Sub-Industry: Pharmaceuticals
Date Listed: 16 Jan 2020
Registry: Automic
Similar Companies: SPL / MYX / AFP / EOF / MVP

Upcoming Calendar

23 Feb 2021 Report (Interim)
30 Aug 2021 Report (Prelim)
7 Sep 2021 Report (Annual)

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.


Date Heading Pages File Size Time

Announcements provided by

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

NYR is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.

Directors & Management

About the Data

Name Title Since Bio
Mr Peter Ashley Marks Non-Executive Director Aug 2017
Dr Ian Edward Dixon Founder, Non-Executive Director Sep 2020
Mr John Alexander Moore Non-Executive Chairman, Non-Executive Director Jun 2019
Mr Ruediger Weseloh Non-Executive Director Jun 2019
Mr Christopher Cox Non-Executive Director Nov 2019
Mr Marcus Frampton Non-Executive Director Jun 2019
Mr David Franks Company Secretary -
Mr James Bonnar Chief Executive Officer -

Director Transactions

About the Data

NYR directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
10/09/20 John Moore Buy +32,500 $0.210 $6,825 On-market trade.
23/04/20 John Moore Buy +35,000 $0.168 $5,882 On-market trade.

Shareholder Distribution

About the Data

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over Total Shareholders
No. of Shareholders 10 212 162 544 107 1,035

Top 20 Shareholders

About the Data

Name Shares Capital
Noxopharm Limited 33,373,245 30.51%
Altnia Holding Pty Ltd 9,921,725 9.07%
Goodridge Nominees Pty Ltd 4,600,000 4.21%
Goodridge Foundation Pty Ltd 3,450,000 3.15%
Colin Housely & Freda Housely 1,863,725 1.70%
Sunset Capital Management Pty Ltd 1,500,000 1.37%
Kohen Enterprises Pty Ltd 1,335,000 1.22%
John W King Nominees Pty Ltd 1,242,483 1.14%
Goodridge Nominees Pty Ltd i 1,212,416 1.11%
Goodridge Foundation Pty Ltd 1,212,416 1.11%
Rhlc Pty Limited 1,000,000 0.91%
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon 885,000 0.81%
Mr Graham Arthur Robinson 878,888 0.80%
Symphony Capital Holdings Llc 800,000 0.73%
Mr Anthony John Locantro 644,000 0.59%
Lawsam Pty Ltd 621,241 0.57%
Baywick Pty Ltd 621,241 0.57%
Mr John Gardner 500,000 0.46%
Phytose Corporation Pty Limited 466,551 0.43%
Mr John Sellers 448,496 0.41%
Carda Pty Ltd 405,000 0.37%
J P Morgan Nominees Australia Pty Limited 360,500 0.33%
All other shareholders 38.43 %

The Top 20 Shareholders of NYR hold 61.57% of shares on issue.

NYR Share Price History

Date Close Change % Change Open High Low Volume Turnover

NYR Historical Data

Download up to 20 years of share price history.

Year Closing Price (30 June) Last Trade
2020 $0.175 30 June

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Development of therapeutic treatments for cardiovascular, neurological and inflammatory/autoimmune diseases, testing and optimization of novel drug candidates while building on the Company's patent portfolio.

Incorporated: --

1209 Orange St
Wilmington Delaware USA 19801

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.